ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRPH ProPhase Labs Inc

5.18
0.13 (2.57%)
Last Updated: 20:36:20
Delayed by 15 minutes
Share Name Share Symbol Market Type
ProPhase Labs Inc NASDAQ:PRPH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.13 2.57% 5.18 5.10 5.25 5.2783 5.05 5.05 41,339 20:36:20

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

08/03/2024 1:00pm

GlobeNewswire Inc.


ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more ProPhase Labs Charts.

ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s Investor website.

REGISTER HERE: https://www.renmarkfinancial.com/events/fourth-quarter-year-end-2023-results-virtual-conference-call-nasdaq-prph-2024-03-15-110000

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.

For more information, visit www.ProPhaseLabs.com.

ProPhase Media Relations and Institutional Investor Contact:ProPhase Labs, Inc.267-880-1111investorrelations@prophaselabs.com

ProPhase Retail Investor Relations Contact:Renmark Financial CommunicationsJohn Boidman514-939-3989Jboidman@renmarkfinancial.com

Source: ProPhase Labs, Inc.

1 Year ProPhase Labs Chart

1 Year ProPhase Labs Chart

1 Month ProPhase Labs Chart

1 Month ProPhase Labs Chart

Your Recent History

Delayed Upgrade Clock